Suppr超能文献

炎症性肠病患者妊娠期间使用硫唑嘌呤和抗 TNF-α 药物的安全性。

Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.

机构信息

Department of Gastroenterology, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, IP, Madrid, Spain.

出版信息

Am J Gastroenterol. 2013 Mar;108(3):433-40. doi: 10.1038/ajg.2012.430. Epub 2013 Jan 15.

Abstract

OBJECTIVES

The safety of thiopurines and anti-tumor necrosis factor-α (TNF-α) drugs during pregnancy remains controversial, as the experience with these drugs in this situation is limited. Our aim is to assess the safety of thiopurines and anti-TNF-α drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy.

METHODS

Retrospective, multicenter study in IBD patients. Pregnancies were classified according to the therapeutic regimens during pregnancy or during the 3 months before the conception: non-exposed group, pregnancies exposed to thiopurines alone (group A), and pregnancies exposed to anti-TNF-α drugs (group B). An unfavorable Global Pregnancy Outcome (GPO) was considered if pregnancy developed with obstetric complications in the mother and in the newborn.

RESULTS

A total of 187 pregnancies in the group A, 66 pregnancies in the group B, and 318 pregnancies in the non-exposed group were included. The rate of unfavorable GPO was different among the three groups (31.8% in non-exposed group, 21.9% in group A, and 34.8% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). The rate of pregnancy complications was similar among the three groups (27.7% in non-exposed, 20.9% in group A, and 30.3% in group B). The rate of neonatal complications was different among the three groups (23.3% in non-exposed group, 13.9% in group A, and 21.2% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). In the multivariate analysis, the treatment with thiopurines (odds ratio = 0.6; 95% confidence interval = 0.4-0.9, P = 0.02) was the only predictor of favorable GPO, whereas maternal age >35 years at conception was the only predictor of unfavorable GPO. The treatment with anti-TNF-α drugs was not associated with an unfavorable GPO.

CONCLUSION

The treatment with thiopurines and anti-TNF-α drugs does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn.

摘要

目的

在怀孕期间,硫嘌呤和抗肿瘤坏死因子-α(TNF-α)药物的安全性仍存在争议,因为在这种情况下,这些药物的经验有限。我们的目的是评估硫嘌呤和抗 TNF-α 药物治疗炎症性肠病(IBD)在怀孕期间的安全性。

方法

对 IBD 患者进行回顾性、多中心研究。根据怀孕期间或受孕前 3 个月的治疗方案对妊娠进行分类:未暴露组、仅暴露于硫嘌呤的妊娠(A 组)和暴露于抗 TNF-α 药物的妊娠(B 组)。如果母亲和新生儿出现产科并发症,则认为总体不良妊娠结局(GPO)不良。

结果

共纳入 A 组 187 例妊娠、B 组 66 例妊娠和未暴露组 318 例妊娠。三组的不良 GPO 发生率不同(未暴露组为 31.8%、A 组为 21.9%和 B 组为 34.8%),硫嘌呤组低于未暴露组(P=0.01)。三组妊娠并发症发生率相似(未暴露组为 27.7%、A 组为 20.9%和 B 组为 30.3%)。三组新生儿并发症发生率不同(未暴露组为 23.3%、A 组为 13.9%和 B 组为 21.2%),硫嘌呤组低于未暴露组(P=0.01)。多变量分析显示,硫嘌呤治疗(比值比=0.6;95%置信区间=0.4-0.9,P=0.02)是 GPO 良好的唯一预测因素,而受孕时母亲年龄>35 岁是 GPO 不良的唯一预测因素。抗 TNF-α 药物治疗与不良 GPO 无关。

结论

硫嘌呤和抗 TNF-α 药物治疗似乎不会增加妊娠期间并发症的风险,并且似乎对新生儿是安全的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验